Cytokinetics Incorporated Quick Ratio (CYTK) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cytokinetics Incorporated  (NASDAQ: CYTK)

Cytokinetics Incorporated's Quick Ratio

CYTK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 3.2 below Cytokinetics Incorporated average.

Within Major Pharmaceutical Preparations industry 73 other companies have achieved higher Quick Ratio than Cytokinetics Incorporated in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 329, from total ranking in the second quarter 2026 at 612.

Explain Quick Ratio?
How much Cash & cash equivalents CYTK´s has?
What are CYTK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CYTK/financial-strength
https://api.csimarket.com/api/v1/companies/CYTK/fundamentals
https://api.csimarket.com/api/v1/companies/CYTK/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CYTK Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 190.89 %
Y / Y Cash & cash equivalent Change 17.4 %
Quick Ratio MRQ 3.2
CYTK's Total Ranking # 329
Seq. Current Liabilities Change 94.8 %
Seq. Cash & cash equivalent Change -56.71 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 74
Healthcare Sector # 108
Overall Market # 329


Quick Ratio Statistics
High Average Low
33.86 9.13 1.81
(Dec 31 2020)   (Sep 30 2013)




Financial Statements
Cytokinetics Incorporated's Current Liabilities $ 353 Millions Visit CYTK's Balance sheet
Cytokinetics Incorporated's Cash & cash equivalent $ 1,130 Millions Visit CYTK's Balance sheet
Source of CYTK's Sales Visit CYTK's Sales by Geography


Cumulative Cytokinetics Incorporated's Quick Ratio

CYTK's Quick Ratio for the trailling 12 Months

CYTK Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 67.92 %
Y / Y Cash & cash equivalent TTM Growth 41.89 %
Quick Ratio TTM 6.07
Total Ranking TTM # 3722
Seq. Current Liabilities TTM Growth 34.9 %
Seq. Cash & cash equivalent TTM Growth 3.18 %

Quick ratio ranking by company, industry and sector >> Back to CYTK Financial Strength Comparisons >> Go to Compare CYTK Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $353.42 millions, cumulative Quick Ratio decreased to 6.07 above the CYTK average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Cytokinetics Incorporated. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3302 to 3722.

Explain Quick Ratio?
How much Cash & cash equivalents CYTK´s has?
What are CYTK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 428
Healthcare Sector # 872
Within the Market # 3722


trailing twelve months Quick Ratio Statistics
High Average Low
6.58 1.84 0.5
(Jun 30 2012)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Ideaya Biosciences Inc   8.70 $ 838.541  Millions$ 96.405  Millions
Bicara Therapeutics Inc   8.63 $ 442.346  Millions$ 51.231  Millions
First Tracks Biotherapeutics Inc   8.60 $ 155.627  Millions$ 18.090  Millions
Arvinas Inc   7.98 $ 558.400  Millions$ 70.000  Millions
Wave Life Sciences Ltd   7.87 $ 431.012  Millions$ 54.760  Millions
Rigel Pharmaceuticals Inc  7.79 $ 224.456  Millions$ 28.806  Millions
Cytomx Therapeutics Inc   7.64 $ 347.980  Millions$ 45.532  Millions
Atea Pharmaceuticals Inc   7.64 $ 191.199  Millions$ 25.025  Millions
Viking Therapeutics Inc   7.17 $ 959.813  Millions$ 133.897  Millions
Scynexis Inc   7.09 $ 47.165  Millions$ 6.652  Millions
Lb Pharmaceuticals Inc  7.03 $ 215.075  Millions$ 30.573  Millions
Zentalis Pharmaceuticals Inc   7.03 $ 228.893  Millions$ 32.539  Millions
Quoin Pharmaceuticals Ltd   6.95 $ 33.184  Millions$ 4.776  Millions
Vera Therapeutics Inc   6.89 $ 384.042  Millions$ 55.775  Millions
Nuvation Bio Inc   6.73 $ 663.370  Millions$ 98.559  Millions
Arcturus Therapeutics Holdings Inc   6.52 $ 184.817  Millions$ 28.345  Millions
Moonlake Immunotherapeutics  6.50 $ 379.704  Millions$ 58.430  Millions
Camp4 Therapeutics Corporation  6.27 $ 124.522  Millions$ 19.865  Millions
Cartesian Therapeutics Inc   6.12 $ 122.975  Millions$ 20.088  Millions
Summit Therapeutics Inc   5.71 $ 629.899  Millions$ 110.226  Millions
Nurix Therapeutics Inc   5.51 $ 720.458  Millions$ 130.742  Millions
United Therapeutics Corporation  5.51 $ 3,439.800  Millions$ 624.300  Millions
Immuneering Corporation  5.45 $ 58.776  Millions$ 10.791  Millions
Aquestive Therapeutics Inc   5.22 $ 90.349  Millions$ 17.299  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Shattuck Labs Inc   4.84 $ 61.758  Millions$ 12.758  Millions
Neurogene Inc   4.35 $ 78.942  Millions$ 18.163  Millions
Entrada Therapeutics Inc   4.34 $ 112.302  Millions$ 25.863  Millions
Gyre Therapeutics Inc   4.34 $ 86.190  Millions$ 19.874  Millions

Date modified: 2026-11-05T09:33:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.